Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1952.03 Billion KRW | 1.43% |
| 2022 | 1924.58 Billion KRW | -0.63% |
| 2021 | 1936.72 Billion KRW | 2.91% |
| 2020 | 1882.02 Billion KRW | -1.66% |
| 2019 | 1913.7 Billion KRW | 13.16% |
| 2018 | 1691.2 Billion KRW | 1.82% |
| 2017 | 1660.93 Billion KRW | 4.01% |
| 2016 | 1596.97 Billion KRW | -7.29% |
| 2015 | 1722.59 Billion KRW | 66.7% |
| 2014 | 1033.33 Billion KRW | 17.31% |
| 2013 | 880.86 Billion KRW | 5.42% |
| 2012 | 835.59 Billion KRW | 6.07% |
| 2011 | 787.75 Billion KRW | 5.35% |
| 2010 | 747.72 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1975.72 Billion KRW | 0.27% |
| 2024 Q1 | 1970.34 Billion KRW | 0.94% |
| 2023 Q4 | 1952.03 Billion KRW | 2.04% |
| 2023 Q1 | 1996 Billion KRW | 3.71% |
| 2023 FY | 1952.03 Billion KRW | 1.43% |
| 2023 Q3 | 1912.99 Billion KRW | 2.52% |
| 2023 Q2 | 1865.96 Billion KRW | -6.52% |
| 2022 Q4 | 1924.58 Billion KRW | -3.0% |
| 2022 FY | 1924.58 Billion KRW | -0.63% |
| 2022 Q1 | 1975.38 Billion KRW | 2.0% |
| 2022 Q2 | 1940.32 Billion KRW | -1.77% |
| 2022 Q3 | 1984.05 Billion KRW | 2.25% |
| 2021 Q2 | 1925.94 Billion KRW | -0.7% |
| 2021 Q1 | 1939.53 Billion KRW | 3.06% |
| 2021 Q3 | 1948.1 Billion KRW | 1.15% |
| 2021 FY | 1936.72 Billion KRW | 2.91% |
| 2021 Q4 | 1936.72 Billion KRW | -0.58% |
| 2020 Q3 | 1947.32 Billion KRW | -1.3% |
| 2020 Q2 | 1973.03 Billion KRW | -0.05% |
| 2020 FY | 1882.02 Billion KRW | -1.66% |
| 2020 Q1 | 1974.11 Billion KRW | 3.16% |
| 2020 Q4 | 1882.02 Billion KRW | -3.35% |
| 2019 Q2 | 1892.72 Billion KRW | 1.92% |
| 2019 FY | 1913.7 Billion KRW | 13.16% |
| 2019 Q4 | 1913.7 Billion KRW | -0.95% |
| 2019 Q3 | 1932.13 Billion KRW | 2.08% |
| 2019 Q1 | 1857.03 Billion KRW | 9.81% |
| 2018 Q4 | 1691.2 Billion KRW | -2.93% |
| 2018 Q3 | 1742.31 Billion KRW | -0.37% |
| 2018 Q2 | 1748.84 Billion KRW | 3.78% |
| 2018 FY | 1691.2 Billion KRW | 1.82% |
| 2018 Q1 | 1685.11 Billion KRW | 1.46% |
| 2017 Q4 | 1660.93 Billion KRW | 1.16% |
| 2017 FY | 1660.93 Billion KRW | 4.01% |
| 2017 Q2 | 1539.18 Billion KRW | 4.13% |
| 2017 Q3 | 1641.94 Billion KRW | 6.68% |
| 2017 Q1 | 1478.08 Billion KRW | -7.44% |
| 2016 Q2 | 1537.62 Billion KRW | -2.8% |
| 2016 Q4 | 1596.97 Billion KRW | 5.54% |
| 2016 Q3 | 1513.15 Billion KRW | -1.59% |
| 2016 FY | 1596.97 Billion KRW | -7.29% |
| 2016 Q1 | 1581.84 Billion KRW | -8.17% |
| 2015 Q3 | 1179.27 Billion KRW | 3.69% |
| 2015 Q1 | 1054.2 Billion KRW | 2.02% |
| 2015 Q2 | 1137.27 Billion KRW | 7.88% |
| 2015 FY | 1722.59 Billion KRW | 66.7% |
| 2015 Q4 | 1722.59 Billion KRW | 46.07% |
| 2014 Q1 | 987.79 Billion KRW | 12.14% |
| 2014 FY | 1033.33 Billion KRW | 17.31% |
| 2014 Q2 | 1001.87 Billion KRW | 1.43% |
| 2014 Q4 | 1033.33 Billion KRW | 1.51% |
| 2014 Q3 | 1017.98 Billion KRW | 1.61% |
| 2013 Q4 | 880.86 Billion KRW | 1.09% |
| 2013 Q2 | 869.29 Billion KRW | 0.8% |
| 2013 FY | 880.86 Billion KRW | 5.42% |
| 2013 Q1 | 862.41 Billion KRW | 3.21% |
| 2013 Q3 | 871.36 Billion KRW | 0.24% |
| 2012 FY | 835.59 Billion KRW | 6.07% |
| 2012 Q2 | 845.56 Billion KRW | 2.24% |
| 2012 Q3 | 844.57 Billion KRW | -0.12% |
| 2012 Q4 | 835.59 Billion KRW | -1.06% |
| 2012 Q1 | 827.01 Billion KRW | 0.0% |
| 2011 Q2 | 683.03 Billion KRW | -2.98% |
| 2011 Q3 | 676.49 Billion KRW | -0.96% |
| 2011 FY | 787.75 Billion KRW | 5.35% |
| 2011 Q1 | 703.99 Billion KRW | 0.0% |
| 2010 Q3 | 684.83 Billion KRW | 0.0% |
| 2010 FY | 747.72 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -884.814% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 0.259% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -122.581% |
| HANDOK Inc. | 790.33 Billion KRW | -146.987% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -1044.084% |
| Yuhan Corporation | 2814.07 Billion KRW | 30.633% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | -48.419% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -1988.206% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -714.206% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -316.298% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -1597.816% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -725.215% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -460.308% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -884.814% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -365.668% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -290.582% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -231.192% |
| JW Holdings Corporation | 1176.26 Billion KRW | -65.952% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -219.346% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | -39.19% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -202.623% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -457.591% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -1167.217% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -426.609% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -300.56% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -884.814% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | -81.068% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | -10.265% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -202.623% |
| Yuhan Corporation | 2814.07 Billion KRW | 30.633% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | -121.823% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -761.442% |
| Suheung Co., Ltd. | 993.73 Billion KRW | -96.434% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -202.623% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -364.88% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -316.336% |
| CKD Bio Corp. | 293.78 Billion KRW | -564.443% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -284.26% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -245.51% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -386.517% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -457.591% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | -34.068% |
| Boryung Corporation | 922.36 Billion KRW | -111.635% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -341.176% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -316.298% |
| JW Lifescience Corporation | 255.83 Billion KRW | -663.001% |